Mamta Kalra
Vice President, CMC Process & Analytical Immatics
Mamta Kalra leads Process Development, Analytical development, and Vector Operations at Immatics. Immatics is a clinical stage biotechnology company and the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. She oversees process and analytics for pivotal-stage TCR-T cell therapy program, anzu-cel (anzutresgene autoleucel; IMA203) in preparation for BLA submission.
With over 20 years in immunology and 15+ years in cell and gene therapy, Mamta has guided the development of anzu-cel program from preclinical research through late-stage clinical development. Her work centers on process characterization and validation, assay validation, commercial scalability, and automation strategies with a strong focus on manufacturing efficiency.
Mamta completed her postdoctoral training at the Center for Cell and Gene Therapy, Baylor College of Medicine and holds a Ph.D. in tuberculosis vaccine development.
Seminars
- Implementing proactive comparability strategies during late-stage development to manage process changes and scale-out requirements while maintaining condensed BLA timelines
- Transitioning products from early clinical phases through commercial readiness by establishing robust comparability frameworks that satisfy evolving regulatory expectations
- Leveraging successful comparability case studies and strategic regulatory navigation approaches to prevent delays and ensure seamless progression toward commercial approval
